BIOCRYST PHARMACEUTICALS INC (BCRX)
Health Care · biotechnology · NASDAQ
BioCryst is a rare-disease-focused biotech company commercializing the once-daily oral HAE therapy ORLADEYO while developing a pipeline of next-generation treatments.
What BIOCRYST PHARMACEUTICALS INC does
BioCryst Pharmaceuticals is a biotechnology company focused on the development and commercialization of medicines for hereditary angioedema (HAE) and other rare diseases. The company markets ORLADEYO, an oral once-daily therapy for the prevention of HAE attacks, and is advancing a pipeline of therapeutic candidates including injectable monoclonal antibodies and protein therapeutics. Following a 2026 strategic shift, the company is prioritizing external innovation and efficient capital allocation to support the growth of its rare disease portfolio.
Themes: rare diseases, hereditary angioedema (HAE), drug commercialization, clinical-stage pipeline
Fundamentals
- Price$9.55 as of 2026-08-21 close
- Market cap$2.4B as of 2026-08-21
- 1-year return+14.0% 2025-08-21 close $8.38 → 2026-08-21 close $9.55
- P/E9.56 as of 2026-08-24
- Net margin-40.9% as of 2026-08-24
- Gross margin+97.8% as of 2026-08-24
- ROE-328.8% as of 2026-08-24
- Debt / equity2.26 as of 2026-08-24
- Revenue growth (YoY)+68.7% as of 2026-08-24
- Revenue CAGR (3y)+22.8% SEC XBRL
- Beta0.55 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How BCRX compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
BCRX is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
57.3 #356 of 1,704 scored · #68 of 240 in Health Care
Setup 64th: no fresh 20-day breakout up or down; momentum 61st: MACD momentum is positive; weakest is trend 48th: the price is 2% below the average price paid over the period covered, so the typical buyer over that stretch is under water.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How BIOCRYST PHARMACEUTICALS INC looks technically
BIOCRYST PHARMACEUTICALS INC (BCRX) is trading 13.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 96 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive). It made a new 20-day high about 8 trading days ago.
Trend
7
| Distance from the 200-day | it is trading 13.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +13.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $9.59 | $9.59 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.41 | $8.41 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 96 trading days ago — a "golden cross", a bullish long-term signal | 96 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 18.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30) | 48.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($8.76 to $10.68) — its "stochastic" reading is 41 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 41.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 10 trading days ago (its momentum flipped positive) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $11.22 | $11.22 |
|---|---|---|
| From the 52-week high | it is 14.9% below its 52-week high (its highest price of the past year) | -14.9% |
| Above the 52-week low | it is 59.2% above its 52-week low (its lowest price of the past year) | +59.2% |
| Below the 52-week high | it is 14.9% below its highest point of the past year | 14.9% |
| Since a 20-day breakout | it made a new 20-day high about 8 trading days ago | 8 sessions |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $23.00 (set on 2006-01-17) | $23.00 |
| Given back of the 52-week move | over the past year its closes ranged ($6.24 to $11.11), and it has given back roughly a third of its rise from last year’s low — 32% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.94 to $8.10. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 32.0% |
| From the all-time high | it is 58.5% below its all-time high | -58.5% |
| Nearest price level | it is trading 3.4% below a resistance level at $9.87 — a price it turned at four times since 2025-05-14, most recently on 2026-07-27. Since 2024-08-21 it has 12 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.4% |
| All-time low | its lowest closing price on record is $0.85 (set on 2008-11-20) | $0.85 |
| Above the all-time low | it is 1023.5% above its all-time low | +1,024% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 48th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4775 between its high and its low — about 5.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4775 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $8.71 and $10.48 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $8.71 – $9.59 – $10.48 |
| Typical daily range (% of price) | its price moves about 5.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.0% |
| Stretch from the 200-day average | it is trading 2.4 daily ranges above its 200-day average price (13.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.75× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 9 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 9 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.6% |
|---|---|---|
| Open gap | it gapped 4.5% above the previous close 46 sessions ago and has not traded back through the level it left behind at 8.7 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.5% |
| Gap filled | a 2.4% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -5.16% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.0 percentage points (the stock gained 1.4% while the market gained 2.3%) | -0.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 11.0 percentage points (the stock gained 14.1% while the market gained 3.1%) | +11.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 17.1 percentage points (the stock gained 28.2% while the market gained 11.1%) | +17.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 6.5 percentage points (the stock gained 14.0% while the market gained 20.5%) | -6.5% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 4.2% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $8.83 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +8.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $9.74 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -2.0% |
Price levels it has turned at before
BCRX last closed at $9.55 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $9.87 | Resistance | 3.4% above the last close | turned there four times · 2025-05-14 to 2026-07-27 |
| $9.20 | Support | 3.7% below the last close | turned there three times · 2025-07-09 to 2026-05-27 |
| $8.91 | Support | 6.7% below the last close | turned there three times · 2024-09-03 to 2026-07-17 |
| $8.72 | Support | 8.7% below the last close | turned there twice · 2025-08-27 to 2026-08-04 |
| $11.21 | Resistance | 17.4% above the last close | turned there three times · 2025-05-05 to 2026-07-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · trendless / choppy (low ADX) · beating the market · Under water since its last earnings report (below the anchored VWAP) · Trading inside the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.45 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$20.82 range $12.00 – $32.00; median $17.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BCRX
- Consensus EPS estimate$0.115 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Uncertainty regarding commercial success and revenue growth for ORLADEYO in competitive markets.","Dependence on successful development and regulatory approval of clinical-stage product candidates like navenibart.","Risks associated with manufacturing, supply chain, and potential delays in product fulfillment."]
What changed in the latest 10-Q
AI-assisted comparison of BCRX's 10-Q filed 2026-05-06 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- In December 2025, the FDA approved an oral pellet formulation of once-daily ORLADEYO for prophylactic therapy in pediatric patients with HAE aged 2 to <12 years (newer filing, filed 2026-05-06)
- Company anticipates seasonal impact to business in the first quarter of each year due to prescription reauthorization requirements from payors (newer filing, filed 2026-05-06)
- On May 6, 2026, company announced a manufacturing issue that will delay the initial product fulfillment of the oral pellet formulation of ORLADEYO (newer filing, filed 2026-05-06)
- Navenibart (STAR-0215) section describing acquisition from Astria on January 23, 2026, including Phase 3 clinical development status, Fast Track and Orphan Drug designations, and European Commission Orphan Medicinal Product Designation (newer filing, filed 2026-05-06)
- STAR-0310 section describing OX40 antagonist monoclonal antibody acquired from Astria for treatment of atopic dermatitis, currently in Phase 1a trial (newer filing, filed 2026-05-06)
- Removed:
- Reference to 'oral granule formulation' and APeX-P clinical trial continuing to assess granule formulation (older filing, filed 2025-11-04)
- PDUFA goal date of December 12, 2025 for new drug application for ORLADEYO granules in children aged 2 to 11 (older filing, filed 2025-11-04)
- Avoralstat product candidate section describing plasma kallikrein inhibitor for diabetic macular edema treatment (older filing, filed 2025-11-04)
- Statement that RAPIVAB has been important component of U.S. Government's influenza preparedness efforts since 2009 H1N1 pandemic (older filing, filed 2025-11-04)
- Revenues and Expenses section beginning (older filing, filed 2025-11-04)
- Reworded:
- Changed from 'launch and continued success of ORLADEYO' to 'successful commercialization of ORLADEYO' in Overview section (newer filing, filed 2026-05-06)
- Changed from 'oral capsule, once-daily therapy' to 'oral, once-daily therapy' describing ORLADEYO formulation (newer filing, filed 2026-05-06)
- Changed from 'nearly five years of commercialization experience' to 'over five years of commercialization experience' (newer filing, filed 2026-05-06)
- Changed from 'more effectively optimize' to 'most effectively optimize' in business strategy statement (newer filing, filed 2026-05-06)
- Revenue discussion period changed from 'three and nine months ended September 30, 2025' to 'three months ended March 31, 2026' (newer filing, filed 2026-05-06)
- Notes:
- Newer filing text appears truncated at STAR-0310 section, limiting complete comparison
- Older filing text also truncated at Revenues and Expenses section
Risk Factors
- Added:
- New statement: 'Although we achieved net income on a U.S. GAAP basis for the year ended December 31, 2025 for the first time on an annual basis, we have not yet achieved sustained profitability.' (2026-05-06 filing)
- New disclosure: 'For example, as a result of the accounting treatment for the Merger, we recorded a net loss on a U.S. GAAP basis for the quarter ended March 31, 2026, due to a special, non-cash charge related to the acquired in-process research and development asset for navenibart.' (2026-05-06 filing)
- New phrase: 'obtain additional financing' added to title and throughout text (2026-05-06 filing)
- New text: 'Additional borrowings may subject us to more restrictive covenants than are currently applicable to us under the Blackstone Loan Agreement.' (2026-05-06 filing)
- New detailed liquidity factors: 'the progress and results of our current and proposed clinical trials for our product candidates; and the progress made in the manufacture of our lead products and the progression of our other programs.' (2026-05-06 filing)
- New text: 'the progression of our product candidates, including the progress, timeline and ultimate outcome of our development programs (including, but not limited to, formulation progress, long-term human safety studies, clinical trial investigations, and carcinogenicity, drug-drug interaction, toxicity, or other required studies), as well as any post-approval studies for our products' (2026-05-06 filing)
- New text: 'Constriction and volatility in the equity and debt markets, including as a result of the impacts of inflation, increased interest rates, disruption or instability in the banking industry, geopolitical instability, or public health emergencies such as the COVID-19 pandemic, may restrict our future flexibility to raise capital if and when such needs arise.' (2026-05-06 filing)
- New text: 'Furthermore, we have exposure to many different industries, financing partners and counterparties, including commercial banks, investment banks and partners (which include investors, licensing partners, distribution partners, and others), which may be unstable or may become unstable in the current economic and political environment, including as a result of the' (2026-05-06 filing, appears to continue)
- Removed:
- Removed: 'Since our inception, we have not achieved sustained profitability.' (2025-11-04 filing)
- Removed reference to 'Pharmakon Loan Agreement' (2025-11-04 filing)
- Removed: 'pursue royalty or other monetization transactions' (2025-11-04 filing)
- Removed: 'royalty or other monetization transactions,' (2025-11-04 filing)
- Removed: 'as applicable, royalties on certain revenues from ORLADEYO under the Royalty Purchase Agreements (as defined in " Note 7— Royalty Financing Obligations " in the Notes to Condensed Consolidated Financial Statements' changed to include 'the' (2025-11-04 filing)
- Removed extensive liquidity discussion text: 'the progression of our product candidates in the future, and our ability to execute our budget plans. Our current plans for managing our liquidity needs primarily include controlling the timing and spending on our research and development programs and commercializing our approved products.' replaced with expanded version (2025-11-04 filing)
- Removed paragraph: 'There can be no assurance that any of our plans will be successful or that additional capital will be available to us on reasonable terms, or at all, if needed. If we are unable to obtain sufficient additional capital if and when needed, we may be forced to adjust or curtail our operations; delay, reduce, or stop ongoing clinical trials or commercialization efforts; cease operations altogether; or file for bankruptcy.' (2025-11-04 filing)
- Removed entire section: 'Risks Relating to the Proposed Merger' with subsections about failure to complete Merger and business uncertainties during pending Merger (2025-11-04 filing)
- Reworded:
- Changed from 'We may need to raise additional capital in the future' to 'We may need to raise additional capital or obtain additional financing in the future' and updated title accordingly (2026-05-06 vs 2025-11-04)
- Changed from 'were applicable to us under the Pharmakon Loan Agreement' to 'are currently applicable to us under the Blackstone Loan Agreement' indicating a loan agreement change (2026-05-06 vs 2025-11-04)
- Expanded liquidity discussion to include more detailed factors about product development timelines and safety studies rather than generic 'in the future' language (2026-05-06 vs 2025-11-04)
- Notes:
- Older filing text appears truncated at end of 'Risks Relating to the Proposed Merger' section, limiting ability to assess complete removal
- Page number changed from 51 to 46, indicating restructuring of document
- The removal of the entire Merger-related risk section is significant given that text explicitly discusses the Merger, which appears to have closed by the 2026-05-06 filing date
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 2 sells ($696535) — 2 selling insiders
Most recent open-market transaction: 2026-05-18. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BCRX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for BCRX from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding BCRX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 38,122,470
- Reported value $362,925,906
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BCRX had 32,804,839 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BCRX had 12.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.43 days to cover at the same settlement.
- Reported short interest (shares) 32,804,839
- Short interest (% of shares outstanding) 12.8%
- Prior settlement (shares) 31,208,457
- Reported change 5.12%
- Days to cover (reported) 12.43
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Takeda Pharmaceutical (TAK)
- CSL (CSLLY)
- Pharming Group (PHGUF)
- Ionis Pharmaceuticals (IONS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BCRX vs…
BIOCRYST PHARMACEUTICALS INC is found in…
Frequently asked questions
What does BIOCRYST PHARMACEUTICALS INC (BCRX) do?
BioCryst Pharmaceuticals is a biotechnology company focused on the development and commercialization of medicines for hereditary angioedema (HAE) and other rare diseases. The company markets ORLADEYO, an oral once-daily therapy for the prevention of HAE attacks, and is advancing a pipeline of therapeutic candidates including injectable monoclonal antibodies and protein therapeutics.
What sector is BIOCRYST PHARMACEUTICALS INC (BCRX) in?
BIOCRYST PHARMACEUTICALS INC (BCRX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are BIOCRYST PHARMACEUTICALS INC's (BCRX) competitors?
Notable peers of BIOCRYST PHARMACEUTICALS INC (BCRX) include Takeda Pharmaceutical, CSL, Pharming Group and Ionis Pharmaceuticals. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in BCRX?
Yes — we hold 1 matched STOCK Act disclosure for BCRX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is BIOCRYST PHARMACEUTICALS INC (BCRX) overbought or oversold right now?
BIOCRYST PHARMACEUTICALS INC (BCRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 49, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BCRX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.